Primary Radiotherapy In MEtastatic Lung Cancer

Lung cancer has the highest mortality rate of all cancers in Australia and is an area of unmet need. It starts in the lung (the primary tumour), and then spreads (metastasise) to other organs. The PRIME-Lung clinical trial will investigate if radiotherapy to the primary lung tumour, in addition to standard drug therapies, for patients with metastatic lung cancer will lead to less spread of cancer, prolong life, improve patient well-being and be cost-effective for the health care system.

Primary Sponsor

Trans Tasman Radiation Oncology Group (TROG)

Collaborating Groups

Thoracic Oncology Group of Australasia (TOGA), Canadian Pulmonary Radiation Investigators (CAPRI), Irish Cancer Trials (ICTG) & Peter MacCallum Cancer Centre / AURORA

Participating Centres

Accrual Target

420

Current Accrual

Expected Date of Accrual

31 December 2030

Trial Chairperson

Prof Shankar Siva, Peter MacCallum Cancer Centre, VIC, Australia

Trial Contact

Clinical Trial Registration

Related Post

27 October, 2026

MASTERPLAN trial shows benefit from SBRT in pancreatic cancer

LATEST NEWS: 27 October 2026 Findings from the AGITG/TROG

21 October, 2026

Jess’s deeply personal reason for joining TROG’s Km’s for Cancer Research challenge

LATEST NEWS: 21 October 2026 For Jess Synge, taking